HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of severe hepatic injury by interferon-alpha in chronic active hepatitis lacking HBeAg (mutant strain) in a patient with malignant lymphoma.

Abstract
Multidrug chemotherapy with concomitant interferon (IFN)-alpha was performed in a patient with chronic hepatitis lacking the hepatitis Be antigen and malignant lymphoma (ML). Levels of trans-aminases and DNA polymerase (DNA-P) values increased after the fifth course of chemotherapy. Therapy with IFN-alpha for 9 weeks induced a remission in liver disease and complete remission of ML was obtained with subsequent chemotherapy. It was possible to prevent severe liver damage by administering IFN immediately after the elevation of DNA-P. Early introduction of IFN may be effective in the prevention of fulminant hepatic failure from hepatitis from a precore mutant after chemotherapy.
AuthorsH Kondo, Y Kasahara
JournalCancer letters (Cancer Lett) Vol. 125 Issue 1-2 Pg. 171-5 (Mar 13 1998) ISSN: 0304-3835 [Print] Ireland
PMID9566712 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Hepatitis B e Antigens
  • Interferon-alpha
Topics
  • Hepatic Encephalopathy (prevention & control)
  • Hepatitis B e Antigens (analysis)
  • Hepatitis, Chronic (therapy)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Lymphoma (drug therapy)
  • Male
  • Middle Aged
  • Virus Activation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: